SG10201406178WA - Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (s1p2) receptors - Google Patents

Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (s1p2) receptors

Info

Publication number
SG10201406178WA
SG10201406178WA SG10201406178WA SG10201406178WA SG10201406178WA SG 10201406178W A SG10201406178W A SG 10201406178WA SG 10201406178W A SG10201406178W A SG 10201406178WA SG 10201406178W A SG10201406178W A SG 10201406178WA SG 10201406178W A SG10201406178W A SG 10201406178WA
Authority
SG
Singapore
Prior art keywords
sphingosine
subtype
receptors
phosphate
condensed ring
Prior art date
Application number
SG10201406178WA
Other languages
English (en)
Inventor
Wenkui Ken Fang
Liming Wang
Evelyn G Corpuz
Ken Chow
Wha Bin Im
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of SG10201406178WA publication Critical patent/SG10201406178WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG10201406178WA 2009-09-29 2010-09-28 Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (s1p2) receptors SG10201406178WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24664209P 2009-09-29 2009-09-29

Publications (1)

Publication Number Publication Date
SG10201406178WA true SG10201406178WA (en) 2014-11-27

Family

ID=43031503

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201406178WA SG10201406178WA (en) 2009-09-29 2010-09-28 Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (s1p2) receptors

Country Status (15)

Country Link
US (2) US8507682B2 (zh)
EP (1) EP2483245A1 (zh)
JP (1) JP2013506003A (zh)
KR (1) KR20120087932A (zh)
CN (1) CN102741232A (zh)
AU (1) AU2010300791A1 (zh)
BR (1) BR112012007095A2 (zh)
CA (1) CA2775587A1 (zh)
IL (1) IL218843A0 (zh)
MX (1) MX2012003718A (zh)
NZ (1) NZ599595A (zh)
RU (1) RU2012114718A (zh)
SG (1) SG10201406178WA (zh)
WO (1) WO2011041287A1 (zh)
ZA (1) ZA201202366B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9663511B2 (en) * 2012-03-26 2017-05-30 Arroyo BioSciences, LLC Sphingosine 1-phosphate receptor antagonists
WO2014158302A1 (en) * 2013-03-25 2014-10-02 Swenson Rolf Eric Novel sphingosine 1-phosphate receptor antagonists
CA2953208C (en) 2014-06-02 2022-05-10 Dalhousie University Treatment of familial exudative vitreoretinopathy through s1pr2 inhibition
CN107849038A (zh) * 2015-06-01 2018-03-27 达尔豪西大学 S1pr2拮抗剂及其用途
US10858358B2 (en) 2015-06-01 2020-12-08 Dalhousie University S1PR2 antagonists and uses therefor
US10487082B2 (en) 2015-06-01 2019-11-26 Dalhousie University S1PR2 antagonists and uses therefor
CN107382965A (zh) * 2017-08-14 2017-11-24 河南科技大学第附属医院 具有抗肿瘤活性的新型s1p‑1受体激动剂药物分子的合成方法
CN113896646B (zh) * 2020-07-06 2023-06-02 浙江海森药业股份有限公司 一种4-甲基-3-氧代-n-苯基戊酰胺的高效绿色制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146810A3 (de) 1983-12-05 1987-05-13 Solco Basel AG Verfahren zur Herstellung von Sphingosinderivaten
US5110987A (en) 1988-06-17 1992-05-05 Emory University Method of preparing sphingosine derivatives
ZA902794B (en) 1989-04-18 1991-04-24 Duphar Int Res New 3-n substituted carbamoyl-indole derivatives
US5294722A (en) 1992-04-16 1994-03-15 E. R. Squibb & Sons, Inc. Process for the preparation of imidazoles useful in angiotensin II antagonism
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
ATE314342T1 (de) 1997-03-12 2006-01-15 Takara Bio Inc Spingosinanaloga
WO1999012890A1 (fr) 1997-09-11 1999-03-18 Takara Shuzo Co., Ltd. Derives de sphingosine et composition medicamenteuse
WO2001098301A1 (fr) * 2000-06-20 2001-12-27 Japan Tobacco Inc. Composes de pyrazolopyridine et utilisation de ces derniers en tant que medicaments
US20020183762A1 (en) 2001-06-01 2002-12-05 Ams Research Corporation Bone anchor inserters and methods
JP4399253B2 (ja) 2001-06-20 2010-01-13 ワイス プラスミノゲンアクチベーターインヒビター−１（ｐａｉ−１）のインヒビターとしての、置換されたインドール酸誘導体
WO2003020313A1 (fr) * 2001-09-04 2003-03-13 Ono Pharmaceutical Co., Ltd. Medicaments contre les maladies respiratoires renfermant un agent de regulation du recepteur de la sphingosine-1-phosphate
JPWO2003051876A1 (ja) * 2001-12-14 2005-04-28 日本たばこ産業株式会社 ピラゾロピリジン誘導体およびその医薬用途
GB0206876D0 (en) * 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
TW200406385A (en) 2002-05-31 2004-05-01 Eisai Co Ltd Pyrazole compound and pharmaceutical composition containing the same
WO2008154470A1 (en) 2007-06-08 2008-12-18 University Of Connecticut Nhibitor of the receptor activity of the s1p2 receptor for inhibiting pathological angiogenesis in the eye
WO2009074969A2 (en) * 2007-12-12 2009-06-18 University Of Lausanne Sphingosine-1-phosphate, analogs and antagonists for use as medicaments

Also Published As

Publication number Publication date
KR20120087932A (ko) 2012-08-07
WO2011041287A1 (en) 2011-04-07
RU2012114718A (ru) 2013-11-10
JP2013506003A (ja) 2013-02-21
US8703797B2 (en) 2014-04-22
BR112012007095A2 (pt) 2016-04-19
ZA201202366B (en) 2012-12-27
AU2010300791A1 (en) 2012-04-19
US8507682B2 (en) 2013-08-13
MX2012003718A (es) 2012-06-28
CA2775587A1 (en) 2011-04-07
EP2483245A1 (en) 2012-08-08
IL218843A0 (en) 2012-06-28
US20120208840A1 (en) 2012-08-16
NZ599595A (en) 2014-03-28
US20130296361A1 (en) 2013-11-07
CN102741232A (zh) 2012-10-17

Similar Documents

Publication Publication Date Title
ZA201202366B (en) Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (s1p2) receptors
IL238849A (en) Process for the preparation of modulating compounds met – c
IL232112A0 (en) Transduced imidazopyrimidines as modulators of 1gpbar receptors
ZA201303421B (en) Compounds useful as modulators of trpm8
HK1175461A1 (zh) 用作阿來新 受體調控劑之稠合雜環化合物
HK1175462A1 (en) Fused heterocyclic compounds as orexin receptor modulators
EP2599774A4 (en) PYRIDINE COMPOUND WITH CONDENSED CYCLE
EP2583965A4 (en) HETEROCYCLIC RING CONNECTION
EP2776411A4 (en) C3A RECEIVER MODULATORS
IL222313A0 (en) Combination of organic compounds
HRP20190476T1 (hr) Postupak za pripravu modulatora histaminskog h3 receptora
PL2401253T3 (pl) Sposób otrzymywania etorykoksybu
HK1180955A1 (zh) 作為組胺 受體配體的雜環基化合物
GB0908711D0 (en) Preparation of labelled compounds
GB0922023D0 (en) Preparation of n-monofluoroalkyl compounds
HK1171020A1 (en) Process for preparation of pyrimidinylpyrazole compounds
EP2537851A4 (en) PROCESS FOR PREPARING B-GLYCOSIDE COMPOUNDS
IL215022A0 (en) Novel process for the preparation of enaminocarbonyl compounds
EP2563748A4 (en) PROCESS FOR THE PREPARATION OF ALKEN COMPOUND
EP2768814A4 (en) NOVEL NON-STEROID COMPOUNDS AS MODULATORS OF AN ANDROGEN RECEPTOR
ZA201200879B (en) Novel compounds as modulators of glucocorticoid receptors
EP2546235A4 (en) PROCESS FOR THE PREPARATION OF t-BUTOXYCARBONYLAMINE COMPOUNDS
AU2011904606A0 (en) Modulators of C3a receptors
ZA201208583B (en) Process for the preparation of hydroquinones
GB201021416D0 (en) Novel heterocyclic compounds